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Abstract 
Intrapartum fever is associated with excess maternal interventions, as well as higher neonatal 
morbidity. Epidural related maternal fever (ERMF) contributes to the development of 
intrapartum fever. The mechanism(s) for ERMF has remained elusive. Here, we consider 
how inflammatory mechanisms may be modulated by local anesthetic agents and their 
relevance to ERMF. We also critically reappraise the clinical data with regard to emerging 
concepts that explain how anesthetic drug-induced metabolic dysfunction, with or without 
activation of the inflammasome, might trigger the release of non-pathogen, inflammatory 
molecules (danger associated molecular patterns; DAMPs) likely to underlie ERMF.  
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Focused Review 
Since the first description of epidural-related maternal fever (ERMF) more than 25 years 
ago,1 the relationship between ERMF and a potential causative role for local anesthetic agents 
has been consistently demonstrated (Table 1). 2-23  Epidural-related fever occurs in 
approximately 20% of laboring women who receive epidural labor analgesia. The absence of 
epidural-related fever in the non-pregnant population has been attributed to the inhibition of 
fever by inhalational anesthetic agents24 and opioids.25 Thus, there may be mechanisms at 
play specific to the biology and/or process of labor. Despite the well-established association 
between labor epidural analgesia and maternal fever (temperature ≥ 38OC),26 controversy still 
exists surrounding its etiology. Intrapartum fever is associated with maternal interventions 
such as administration of intravenous antibiotics,27 instrumental and cesarean delivery,28 as 
well as higher perinatal mortality 23 and neonatal morbidity such as meconium aspiration, 
respiratory distress syndrome and encephalopathy.18,29 A better understanding of the cause of 
ERMF may allow interventions to be developed that lead to a reduction in its incidence rate 
and also facilitate the differentiation from other causes of intrapartum fever. In this focused 
review, we review the evidence that supports the hypothesis that inflammatory mechanisms 
generated by anesthetic-specific interventions are responsible for the development of ERMF, 
and consider emerging concepts of possible mechanisms.  
 
Infection versus inflammation 
Intuitively, infection would appear to be the most likely trigger for ERMF. Chorioamnionitis, 
the condition of acute inflammation of the membranes and chorion of the placenta, is 
estimated to complicate 3-5% of all births in the United States.30 Although the precise 
frequency of chorioamnionitis varies, the highest estimates are clearly exceeded by the 
prevalence of ERMF (Table 1). More compellingly, a double blind, placebo-controlled 
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adequately powered trial in 400 laboring women found that prophylactic antibiotic therapy 
(broad-spectrum cephalosporin) failed to prevent ERMF.31 In addition, clinically relevant 
models of local anesthetic administration in vivo demonstrate bactericidal activity against 
common pathogens.32,33 The failure of antibiotic prophylaxis to reduce ERMF, combined 
with the consistent lack of positive microbiology in observational studies, 3,34 suggests that 
the etiology of ERMF is not primarily infectious in origin.  
 
The case for systemic inflammation causing ERMF 
There are several compelling clinical clues suggesting that acute inflammation alone 
underlies the mechanism of ERMF. Higher levels of maternal 34 and fetal 35 pro-inflammatory 
endogenous pyrogens that trigger fever have been measured in pregnant patients following 
epidural analgesia. 9,34-36 However, Riley and colleagues reported that pregnant patients who 
subsequently developed ERMF had higher admission levels of pro-inflammatory cytokines 
(interleukin (IL)-6 and IL-8) prior to receiving epidural analgesia,9 suggesting that prolonged 
epidural administration of bupivacaine may augment baseline elevated cytokine levels. 37 38 
Conversely, anti-inflammatory glucocorticoids reduce ERMF, in part through reducing 
cytokine production. In 200 term laboring nulliparous women, prophylactic treatment with 
the high dose intravenous methylprednisolone (100 mg every 4 hours) reduced the rate of 
ERMF to just 2.0% compared with low dose (25 mg every 8 hours; 21.8% incidence) and 
placebo therapy (34.0% incidence).39 However, the marked reduction in ERMF was at the 
expense of excess (asymptomatic) neonatal bacteremia– a finding consistent with profound 
immunosuppression. Dexamethasone administered via epidural infusion (mean total dose 5.8 
mg (range: 3.4-14.2 mg)) was also associated with a reduction in maternal temperature rise 
and lower plasma IL-6 levels 40, although a subsequent study has failed to replicate these 
findings.41.  Taken together, these trials of anti-inflammatory steroid therapy suggest that pro-
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inflammatory pyrogen release is suppressed. However, these studies cannot rule out that 
glucocorticoids may modulate ERMF at the level of the hypothalamus/central nervous 
system. 42  
 
 
What is the source of sterile inflammation in ERMF? 
Given the lack of plausible data supporting an acute infectious etiology for ERMF, alternative 
triggers/sources must fuel inflammation and cytokine production. Sterile inflammation is a 
process through which inflammation occurs in the absence of  a pathogen, 43 driven by 
endogenous molecules called alarmins that are released upon tissue damage.44 Alarmins play 
both homeostatic and pathophysiologic roles via pattern recognition receptors, including 
Toll-like receptors 45 which are ubiquitously expressed by immune and non-immune cells. 
These numerous (and ever-expanding) damage-associated molecular patterns (DAMPs) –
including mitochondrial DNA 46 – activate the inflammasome. The inflammasome is an 
intracellular multiprotein complex that promotes the maturation of the pro-inflammatory 
cytokines IL-1β and IL-18 and subsequent induction of other fever-inducing cytokines. 47  
 
Trauma, stress and inflammation from epidural catheter insertion alone 
Both mental stress 48 and limited surgical trauma are associated with clinically relevant 
inflammation and cytokine release. However, triggering ERMF- related inflammatory 
changes by epidural needle/catheter insertion alone seems highly unlikely. Based on a study 
in orthopedic surgery patients,49 the magnitude of the systemic cytokine release following 
catheterization of the epidural space alone is unlikely to account for the magnitude of the 
systemic inflammatory response associated with ERMF. However, fiberscopic imaging has 
confirmed that the epidural space in pregnancy differs anatomically, revealing a marked 
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increase in the density of the vascular network.50 Local inflammation, therefore, remains a 
possible mechanism of ERMF, particularly given the precedent of procedures triggering a 
systemic inflammatory response. For example, it is notable that pulmonary artery 
catheterization via the internal jugular vein triggers a pro-thrombotic response, as reflected by 
reduced clotting time assessed using thromboelastography.51  
 
Inflammation and labor 
Before and during onset of labor at term, leukocytes and inflammatory cytokines are 
increased in fetal membranes and decidua 52 – even in the absence of infection. 53 54 
Pregnancy in many respects mimics the immune response to  sterile inflammation, with a 
shift to an adaptive immunity phenotype, decreased proliferation of T cells and lower 
cytotoxicity of natural killer cells.55  Proposed sites of cytokine production in pregnancy are 
non-lymphoid tissues, including the placental/decidual tissues and the trophoblast.56  
Spontaneous labor at term is associated with the infiltration of inflammatory cells in these 
tissues and increased production of pro-inflammatory cytokines 57,58 and multiple other 
immunomodulatory molecules.57 Gene expression analyses have revealed that genes involved 
in the control of inflammation are upregulated in the chorioamniotic membranes of women 
with physiologic spontaneous labor at term, even in the absence of histological 
chorioamnionitis. This inflammatory signature is not evident in genes from whole blood 
analysis obtained at the same time from the same patients.59 These findings emphasize that 
spontaneous parturition is associated with an increased pro-inflammatory cytokine 
response.57 There appears to be an inflammatory-specific feature of labor relevant to ERMF 
since maternal fever does not occur in non-laboring women who have an elective cesarean 
delivery under neuraxial anesthesia.60 In part, this may reflect that the development of ERMF 
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is related to the duration of exposure to neuraxial analgesia. This finding implies that the 
inflammatory component of the labor process is integral to the development of ERMF.  
 
A direct mechanistic role for local anesthetic agents. 
The majority of studies report that ERMF occurs within 6 h of the onset of epidural 
analgesia, with temperature increasing progressively after initiation of epidural analgesia. 
This timeframe is compatible with a pharmacologic effect and/or changes in RNA 
transcription caused by local anesthetic agents.  Some have hypothesized that the 
observation that epidural analgesia is associated with fever compared to a control group 
without epidural analgesia is a result of fever suppression by systemic opioid analgesia 
administered to the control group. However, opioids fail to suppress ERMF (Table 1), best 
highlighted by the retrospective finding that the antipyretic effect of intravenous systemic 
nalbuphine in laboring women failed to reduce the incidence rate of ERMF observed in 
women who received nalbuphine prior to receiving epidural analgesia.61 ERMF also occurs 
in the presence and absence of epidural opioid, 19 again suggesting a specific effect exerted 
by local anesthetic agents. Furthermore, albeit in male healthy volunteers, an intravenous 
fentanyl infusion suppressed the febrile response triggered by the pyrogen IL-2.62 The 
development of fever was assessed following epidural analgesia using ropivacaine in the 
presence/ absence of fentanyl, administered either in combination with ropivacaine (2 
mg.ml-1) or as an  intravenous infusion (target plasma concentration of 2.5 ng.ml-1).  Low 
plasma concentrations of fentanyl (~0.3 ng.ml-1) failed to suppress fever, in contrast to 
approximately 5-fold higher plasma concentrations achieved by intravenous fentanyl.62 
Although the raw data were not shown in this paper, the authors commented that the pattern 
of cytokine release was similar between treatment arms in this crossover study. We thus 
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consider there are two labor-specific possibilities for local anesthetics to directly trigger 
ERMF: immunomodulation and cell injury. 
 
 
Immunomodulation 
Local anesthetics used routinely for epidural anesthesia in the labor ward- including 
bupivacaine and ropivacaine- exert profound immunomodulatory effects at plasma levels 
achieved rapidly with continuous epidural infusion.63,64 Steady state maternal venous 
plasma concentrations of bupivacaine approach  4x10-6M. 65-67 At far lower concentrations 
(<10-8M), bupivacaine modulates intracellular calcium signaling triggered by key 
neurotransmitters in astrocytes that have also been identified to play a role in peripheral 
immune cells.68 While the immunomodulatory effects of local anesthetics have been found 
to be clinically useful under some circumstances, 69 the inhibitory effects of local 
anesthetics on neutrophil mobility,70 phagocytosis,71 chemotaxis,72 and superoxide 
generation may also be deleterious.73,74 Despite this spectrum of inhibitory effects, the 
ability of neutrophils to undergo chemotaxis appears to be preserved in laboring women 
with epidural analgesia, given the extent to which they contribute to placental infiltrates.75 
The potential reduction in capacity of leukocyte subsets to counteract ongoing reproductive 
tract inflammation could fuel further systemic inflammation. For example, impaired 
chemotaxis in neutrophils reduces survival in sepsis as a result of failure of bacterial 
clearance. 76 Potentially adverse immunomodulatory actions of bupivacaine have already 
been described in the obstetric population; subcutaneous bupivacaine was associated with a 
reduction in the anti-inflammatory cytokine IL-10 and a concomitant increase in the 
proinflammatory mediator substance P in surgical wounds following cesarean delivery.77  
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Cell injury 
Activated immunocytes require profound metabolic changes in order to respond to various 
acute environmental challenges. For example, the activation of T-lymphocytes is critically 
dependent upon rapid increases in both glycolysis and oxidative phosphorylation. 78,79 
Acute stressors alter the metabolic capacity of lymphocytes.80,81 CD4+ T cells inhibit 
macrophage-dependent release of the pro-inflammatory cytokine IL-1ß.82   Under such 
circumstances, further bioenergetic compromise following the impairment of mitochondrial 
respiration by systemic absorption of epidural bupivacaine may promote apoptosis/necrosis 
and hence the release of pyrogenic DAMPs into the circulation. Several studies have 
described local anesthetic-induced apoptosis in various cell types, including neuronal, 
lymphocytic and osteoblastic cell lines.83-86 Epidural lidocaine in dogs induces apoptosis 
and/or necrosis of peripheral blood mononuclear cells, 87 a finding reproduced in a 
lymphocyte (Jurkat) cell line. 88  In vitro, clinically relevant concentrations of both 
lidocaine and bupivacaine induce apoptosis in primary intervertebral disc cells 89 and 
human renal cells. 90 Studies in both isolated mitochondria and intact cells (albeit obtained 
chiefly from cardiac tissue), show that bupivacaine time- and dose-dependently impairs 
ATP synthesis in aerobic conditions 91 through uncoupling of oxidative phosphorylation92,93 
and inhibition of complexes I 94 and III 95 of the respiratory chain. Although not obligatory, 
generation of reactive oxygen species is associated with activation of the inflammasome. 96 
Cell-specific pathologic changes induced by bupivacaine in highly oxidative tissues such as 
skeletal muscle also include activation of the mitochondrial permeability transition pore, a 
critical event in mitochondrial-dependent programmed cell death. 97  
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The cellular source(s) of alarmins generated by local anesthetic agents 
Systemic absorption of epidurally administered bupivacaine at clinically relevant 
concentrations may cause mitochondrial damage through electron transport chain 
dysfunction, 95 excessive reactive oxygen species and/or apoptosis in circulating leukocytes 
and/or the materno-placental interface (Figure 1). Our recent work has highlighted an 
emerging role for acute stress hormones in modulating leukocyte metabolism. Elevations in 
circulating glucocorticoids‒typical of the labor process‒increase mitochondrial reactive 
oxygen species, activated caspase-1 and mature interleukin (IL)-1β in human lymphocytes. 
This is accompanied by a hypometabolic phenotype and apoptosis. 81 Similarly, 
mitochondrial electron chain dysfunction is generated by acute increases in nitric oxide 98. 
Plasma levels of bupivacaine may be misleading, as suggested by the accumulation of 
bupivacaine in the myocardium resulting in reversible pathologic changes in mitochondrial 
structure and reduced mitochondrial oxygen consumption.99 Thus, accumulation of 
bupivacaine in placental tissues 100 could induce release of alarmins from reproductive tract 
and placental inflammatory cell infiltrates and/or non-lymphoid tissues.56   
 
Conclusion 
Epidural related maternal fever remains a phenomenon of unknown etiology, yet affects a 
significant proportion of laboring women with potentially important clinical consequences. 
Local anesthetic agents routinely utilized for epidural analgesia in labor appear to be the 
likeliest culprits for the development of ERMF. Plausible mechanisms involving bupivacaine 
have already been described in other areas of inflammation biology and relevant clinical 
models. Sterile inflammation and activation of the inflammasome are likely to play a key 
role. From a clinical perspective, more detailed epidemiologic studies comparing high-risk 
versus low-risk laboring women may help reveal biologic differences underlying ERMF.  
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Similarly, establishing whether different local anesthetic agents confer similar risk may shed 
further light on underlying mechanisms. 
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Tables 
 Table 1: Summary of studies describing ERMF  
          
Study Design Fever 
(°C) 
Measu
rement 
Site 
Drugs and Doses Incidence of Fever UOR / 
AOR / 
RR 
(95% CI) 
   Epidural Non-epidural Epidural 
group  
[% 
(n/N)] 
Non-
epidural 
group  
[% 
(n/N)] 
 
Lieberma
n2 
Prospect
ive 
Observat
ional 
≥38 
Not 
stated 
Drugs and doses 
not stated. 
Drugs and 
doses not 
stated. 
14.5 
(152/104
7) 
1.0 
(6/610) 
UOR 
17.10 
(7.51 – 
38.91) 
AOR 14.5 
(6.3 – 
33.2)* 
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Mayer3 Retrospe
ctive 
Observat
ional  
≥37.8 
Oral 
Epidural only 
group (n=97), IV 
opioid and 
epidural group 
(n=94)  
(drugs and doses 
not stated for any 
group) 
 
IV opioid 
(drugs and 
doses not 
stated) 
n=96), 
20.4 
(39/191) 
2.1 
(2/96) 
UOR 
12.06 
(2.85 – 
51.11) 
Kaul4 Prospect
ive 
Observat
ional 
≥38  
Tympa
nic 
3-ml test dose 
1.5% lidocaine 
1:200,000 
epinephrine 
followed by 
bupivacaine 
0.25% or 
ropivacaine 0.2% 
5-mL increments 
up to 10 mL 
(block to T10). 
Followed by 
bupivacaine 
2 mg IV 
butorphanol or 
5–10 mg 
nalbuphine IV 
prn. 
6.6 
(61/922) 
0 (0/255) UOR 
36.48 
(2.25 – 
591.90) 
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0.125% (or 
ropivacaine 0.1%) 
and fentanyl 2 
μg/mL at 10-12 
mL/hr .  
Dashe5 Prospect
ive 
Observat
ional 
≥38 
Not 
stated 
0.125% 
bupivacaine 2 
μg/mL fentanyl 8-
10 ml/h to achieve 
T10 block 
 
prn IV 
meperidine 50-
100 mg every 2 
h 
46.3 
(37/80) 
26.1 
(18/69) 
UOR 2.43  
(1.22 – 
4.88) 
Vinson6 Observat
ional 
≥37.5 
≥38 
Tympa
nic 
Test dose of 
lidocaine followed 
by bolus of 
bupivacaine 
followed by 
infusion at 10-14 
mg/hr and 10-20  
μg/hr sufentanil 
(for all but 1 
patient) 
meperidine or 
nalbuphine  
(dose or route 
not stated) 
26.8 
(11/41) 
14.6 
(6/41) 
8.3 
(3/36) 
0 (0/36) 
UOR 4.03  
(1.03 – 
15.86) 
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Herbst7 Retrospe
ctive 
Observat
ional 
≥38 
Oral 
1989 – 1992 
(0.25% 
bupivacaine 5-8-
mL doses). After 
1993 (first dose 5-
8 ml of 0.125% 
bupivacaine and 
sufentanil 10 μg, 
then 0.125% 
bupivacaine 8 mL 
for further doses)  
Meperidine 
(dose and route 
not stated) 
6.4 
(44/683) 
1.1 
(28/2426
) 
UOR 5.90  
(3.64 – 
9.55) 
AOR 4.3 
(2.4 – 
7.8)* 
Ploecking
er8 
Retrospe
ctive 
Observat
ional  
≥38 
Axillar
y 
4 ml 0.25% 
bupivacaine 15 μg 
epinephrine test 
dose followed by 
10 mL 0.25% 
bupivacaine.  
From 1989 0.025 
mg/mL 
bupivacaine, 2.5 
μg/mL fentanyl 
and 0.0125 μg/mL 
IM tramadol 
100 mg or 75 
mg meperidine 
every 2 h prn 
1.6 
(17/1056
) 
0.2 
(11/6261
) 
UOR 9.30  
(4.43 – 
19.90) 
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epinephrine; rate 
10-12 mL/hr 
Riley9 Prospect
ive 
Observat
ional 
>38 
Oral 
CSE (35/191) or 
epidural. Epidural 
and CSE regimes 
not stated 
Drug and doses 
not stated 
22.7 
(34/150) 
6 (3/50) UOR 4.59 
(1.34 – 
15.68) 
AOR 4.9 
(1.1–
22.4)* 
Macaula
y10 
Prospect
ive 
Observat
ional 
≥37.5  
Uterine 
Epidural 2 ml-1% 
lidocaine, and 10 
mL-0.5% 
bupivacaine.  
 
50:50 N2O:O2 
(n=15), IM 
meperidine  
(n=9); (dose not 
stated) 
 45 
(15/33) 
8 (2/24) UOR 9.17  
(1.85 – 
45.47) 
Halpern1
1 
RCT >38 
Not 
stated 
IV fentanyl; 
PCEA 0.08% 
bupivacaine1.6 
μg/mL fentanyl (5 
mL, 10 min 
lockout interval) 
IV 100 mcg 
fentanyl over 
1–5 min. 
Additional 50 
μg repeated 
every 5 min 
until adequate 
pain relief. 
PCA pump 25 
15(19/12
4) 
8 
(10/118) 
UOR 1.95  
(0.87 – 
4.40) 
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– 50 μg 
fentanyl 10 min 
lockout.  
lockout and 
bolus dose 
varied at 
discretion of 
clinician 
Ramin12 RCT ≥38 
Not 
stated 
Low risk 
parturients. 
Epidural- 3-ml test 
0.25% 
bupivacaine, then 
3-mL increments 
to achieve T10 
block. 0.125% 
bupivacaine and 2 
μg/ mL fentanyl at 
8-10 mL /h 
continuous 
infusion (for T8 
block).  
IV meperidine 
50 mg and 25 
mg 
promethazine, 
then IV 
meperidine 50 
mg as required 
(maximum 200 
mg in 4 hours) 
22.7 
(98/432) 
4.8 
(21/437) 
UOR 5.81  
(3.55 – 
9.51) 
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Sharma13 RCT ≥38 
Not 
stated 
0.25% 
bupivacaine 3-ml 
increments to 
achieve T10 
block. 
Maintenance with 
0.0625% 
bupivacaine and 
2-μg/ mL fentanyl 
at 6- mL /h and 5-
ml bolus every 15 
min (PCEA)  
 
IV meperidine 
50 mg and IV 
promethazine 
25 mg. 
Meperidine 15 
mg with 10-min 
lockout PCA 
and additional 
boluses of IV 
meperidine 25 
mg prn (up to 
100 mg in 2 hr) 
33.2 
(75/226) 
6.9 
(16/233) 
UOR 6.74  
(3.78 – 
12.01) 
Sharma14 RCT ≥38 
Not 
stated 
0.25% 
bupivacaine to 
achieve T10 block 
followed by 
0.125% 
bupivacaine + 2 
μg/ mL fentanyl 8-
10 ml/hr.  
PCA IV 
meperidine 10 
mg bolus , 10-
min lockout 
interval for first 
hour followed 
by 15-mg 
bolus, 10-min 
lockout interval 
23.9 
(58/243) 
6.2 
(16/259) 
UOR 4.76  
(2.65 – 
8.55) 
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until delivery 
with extra 25 
mg for 
breakthrough 
(<100 mg in 2 
h) 
Lucas15 RCT ≥38 
Not 
stated 
Women with 
pregnancy induced 
hypertension 
(diastolic blood 
pressure >90 
mmHg). Epidural 
block to T10 with 
0.25% 
bupivacaine 
followed by 
0.125% 
bupivacaine and 2 
μg/mL fentanyl.  
Initial bolus of 
50 mg IV 
meperidine 25 
mg IV 
promethazine 
followed by 15 
mg IV 
meperidine 
bolus with 10-
min lockout 
interval 
20.4 
(76/372) 
7.1 
(26/366) 
UOR 3.36  
(2.09 – 
5.38) 
AOR 2.9 
(1.5-5.6)* 
De 
orange16 
RCT 
 
≥38  
Axilla 
CSE (2.5 mg 
bupivacaine + 5 
μg sufentanil). 
No medication 
administered 
14 (5/35) 0 (0/35) UOR 
12.80 
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Epidural 5 ml 
0.05% 
bupivacaine + 
sufentanil 0.2 μg/ 
mL every 30 min 
(0.68 – 
241.04) 
Philip 17 RCT 
 
≥38  
Tympa
nic 
Epidural initiated 
with 0.25% 
bupivacaine 
(volume not 
stated) and then 
continuous 
infusion 0.125% 
bupivacaine and 2 
μg/ mL fentanyl 
(volume not 
stated).  
50 mg IV 
meperidine and 
25 mg IV 
promethazine at 
first request and 
15 mg IV 
meperidine 
every 10 min 
via PCA 
15.1 
(54/358) 
4.0 
(14/357) 
AOR 4 
(2.0, 7.7)* 
Impey18 Prospect
ive 
cohort 
study 
>37.5 
Oral 
Drugs and doses 
not stated.  
Drugs and 
doses not 
stated. 
4915 low-risk 
women.  
Higher incidence of 
fever  
in epidural group – 
univariate analysis. 
Not stated 
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Not significant in 
multiple logistic 
regression. 
Camann1
9 
Prospect
ive 
(patient 
choice) 
Not 
stated 
Tympa
nic 
Epidural – 0.25% 
Bupivacaine 8-12 
mL followed by 
either 0.25% 
bupivacaine  at 10 
mL /h or 0.25% 
bupivacaine and 
fentanyl 2 μg/mL 
at 10 mL /h 
 
IV nalbuphine 
10-20 mg ≥ 1 
occasion. 
Frequency not 
stated. 
Higher temperature 
in  
epidural group after 
5 hours 
 
Not stated 
Yancey20 Retrospe
ctive 
Before-
after 
study  
≥37.5 
≥38 
Tympa
nic 
Epidural 3 mL 
1.5% lidocaine 
and 1:200,000 
epinephrine test 
dose then 8 ml 
0.125% 
bupivacaine and 
100 μg fentanyl 
followed by 
Drugs and 
doses not stated 
8.2(41/49
8) 
0.6(3/498
) 
26.2(150
/572) 
11.0 
(63/572) 
RR 20.2 
(7-86) 
(≥38)* 
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infusion of 
0.125% 
bupivacaine and 
2-4 μg/mL 
fentanyl at 10  mL 
/h 
Akerman
21 
Audit  
? 
prospect
ive / 
retrospe
ctive 
≥38 
Not 
stated 
Drugs and doses 
not stated 
Drugs and 
doses not stated 
Higher incidence of 
fever  
in epidural group.  
Epidural (N = 56); 
No epidural (N = 73) 
Not stated 
Reilly22 Retrospe
ctive 
>38ºC 
or  
2 
>37.5º
C 
Oral 
Drugs and doses 
not stated. 
Drugs and 
doses not 
stated. 
1.42 
(156/10,9
99) 
0.09 
(5/5484) 
AOR 5.5  
(4.0– 
7.0)*  
RR 16 
(4.9-51) 
Bensal23 Retrospe
ctive 
≥38 
Not 
stated 
Drugs and doses 
not stated 
Drugs and 
doses not stated 
169,738 vaginal 
deliveries.  
UOR 1.25 
(0.99 - 
1.57) 
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No difference in 
fever in epidural 
group 
 
Reilly- fever defined as an oral maternal temperature >38ºC or 2 consecutive temperatures >37.5ºC after the 
onset of active labor; RCT=randomized controlled trial; UOR = unadjusted odds ratio; AOR = adjusted odds 
ratio; RR = risk ratio; * signify results calculated using logistic regression analysis to adjust for potential 
confounding variables; PCEA=patient controlled epidural analgesia; PCA=patient controlled analgesia; 
CSE=combined spinal-epidural 
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Table 2: Cytokine levels in patients with and without labor epidural analgesia 9 
  
Fever: no fever (n) 
 IL-6 
No fever  
 
Fever 
IL-8 
No fever  
 
Fever 
Epidural 102: 30  228.4  386.2 4.3 5.1 
No Epidural 43: 3  107.6 333.5 2.5 4.2 
 
Median plasma cytokine levels (pg.mL-1; ranges were not reported in original paper) for women 
receiving epidural (n=132) or alternative analgesia during labor (n=46).  
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Figures and Illustrations 
 
Figure Legends  
 
Figure 1: Proposed mechanism by which bupivacaine may cause ERMF. 
Bupivacaine causes cell injury by ‘poisoning’ mitochondria. Injured cells release danger-to-self 
molecules known as alarmins, which provoke immune cells to generate fever-producing 
cytokines (pyrogens). Arrow pointing to uterus represents bupivacaine acting on the 
placenta/membrane. Arrows pointing to mitochondria indicate systemic bupivacaine absorbed 
from the epidural space. Increased levels of reactive oxygen species from injured mitochondria 
can also activate the inflammasome, which promotes the maturation of the inflammatory 
cytokines IL-1β, IL-18 and the induction of other fever-inducing cytokines.  
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